(Q42123431)

English

The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.

scientific article published on July 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. (English)

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

cholecystokinin

1 reference

based on heuristic

inferred from title

author name string

T D Barrett

1

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

G Lagaud

2

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

P Wagaman

3

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

J M Freedman

4

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

W Yan

5

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

L Andries

6

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

M C Rizzolio

7

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

M F Morton

8

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

N P Shankley

9

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

language of work or name

0 references

publication date

1 July 2012

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

British Journal of Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

166

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

5

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1684-1693

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Guide to Receptors and Channels (GRAC), 5th edition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Use of proton pump inhibitors and risk of osteoporosis-related fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Long-term proton pump inhibitor therapy and risk of hip fracture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Pharmacological analysis of CCK2 receptors up-regulated using engineered transcription factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Molecular cloning, expression and pharmacological characterization of the canine cholecystokinin 1 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Problems associated with the clinical use of proton pump inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

The gastrins: their production and biological activities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Marked increase in gastric acid secretory capacity after omeprazole treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Reversibility of the cell kinetic changes induced by omeprazole in the rat oxyntic mucosa. An autoradiographic study using tritiated thymidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

29 May 2018

Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Gastric acid secretion in cholecystokinin-1 receptor, -2 receptor, and -1, -2 receptor gene knockout mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

CCK antagonists: pharmacology and therapeutic interest

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Long-Term Omeprazole Treatment in Man: Effects on Gastric Endocrine Cell Populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419911

17 August 2018

Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/22300007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastric mucosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/22300007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Omeprazole produces parietal cell hypertrophy and hyperplasia in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22300007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversibility of omeprazole-evoked changes in the ultrastructure of ECL cells in the rat stomach

1 reference

https://pubmed.ncbi.nlm.nih.gov/22300007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A close look at acid reflux drugs points to possible risks

1 reference

https://pubmed.ncbi.nlm.nih.gov/22300007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1476-5381.2012.01878.X

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42123431&oldid=1564135047"